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Abstract
Background: The risk factors for the transmission of HCV vary substantially between countries
and geographic regions. The overall prevalence in south and east Africa region has been estimated
to be 1.6% but limited information about the epidemiology of HCV infection in Madagascar is
available
Methods: A cross-sectional survey for hepatitis C antibodies was conducted in 2,169 subjects of
the general population of Antananarivo to determine seroprevalence of hepatitis C and associated
risk factors.
Results:  The overall seroprevalence was 1.2% (25/2,169). The prevalence did not differ
significantly according to gender but it increased with age (Chi2 tendency test, p < 10-5). The
variable history of hospitalization, previous therapeutic injections, dental treatment, intravenous
drug use, and abnormal ALT and AST were statistically significantly related with the presence of
HCV antibodies. No relationship with past history of blood transfusion was observed.
Conclusion: HCV prevalence in Madagascar seems to be similar to that in most other east African
countries. Age appears to be an important risk factor. Iatrogenic causes of HCV transmission need
to be further evaluated because all HCV cases had a history of receiving therapeutic injections and
data suggested a cumulative effect in relation with therapeutic injections.
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Background
Hepatitis C virus (HCV) is a major cause of chronic liver
disease worldwide. In 1999, the WHO estimated a world-
wide prevalence of about 3%, with the virus affecting 170
million people [1]. The major channels for HCV transmis-
sion are all related to exposure to blood and blood prod-
ucts. The risk factors for the transmission of HCV vary
substantially between countries and geographic regions.
In Europe, the general prevalence of antibodies to HCV
(anti-HCV) is about 1% [2]but varies between countries
(0.87% in Belgium [3], 3.2% in Northern Italy [4], 1.3%
in France [5,6]). In Central and South America, the preva-
lence varies between 1.2% [7] (Puerto Rico) and 6.3% [8]
(Mexico). Intermediate rates of HCV infection have been
reported across Asia (0.49% in Japan [9], 1% in China
[10,11]) with higher rates in some areas (Hubei province
– 30.1%, Inner Mongolia Autonomous Region – 31.9%
[12]). The recently estimated prevalence in Australia is
2.3% [13]. There have been fewer studies in Africa; how-
ever, the region is reported to have the highest HCV prev-
alence rate (5.3%) [1] with differences between regions
[14]. Prevalence is generally high in central Africa (6.0%)
[14] with the maximum in Cameroon (13.8%) although
lower rates have been reported (1.9% in pregnant
women) [15]. Nevertheless, much higher rates (20%)
have been found in Egypt [16-18]. In west Africa, the over-
all weighted average prevalence is 2.4% [14]. The highest
HCV prevalence for this region is in Guinea (5.5%) [14].
The overall prevalence in south and east Africa region has
been estimated to be 1.6% [14]: among blood donors
1.6% in Ethiopia and 0.9% in Kenya [19,20]. The lowest
HCV prevalence for this region is in South Africa (0.1%)
[14].
Only limited information about the epidemiology of
HCV infection in Madagascar is available. Previous studies
have suggested a low prevalence of HCV seropositivity
among a sample of patients in rural areas [21-23].
Although HCV infection has been identified as one of the
major causes of chronic hepatitis and hepatocellular carci-
noma in Antananarivo [24], its prevalence in the popula-
tion and routes of transmission are largely unknown. The
aim of this study was to determine the prevalence of anti-
HCV antibodies and the possible risk factors for transmis-
sion in the general population of Antananarivo.
Methods
Study design and setting
Antananarivo (Commune Urbaine d'Antananarivo or CUA)
is the capital city of Madagascar. It is located on the central
highlands. The CUA had a population of about 1.5 mil-
lion in 2004 (report from the Mairie d'Antananarivo-
Ville). Antananarivo consists of administrative, commer-
cial, industrial and residential areas, with patches of agri-
cultural land that are mostly rice fields. The city is divided
into six administrative districts.
The study was carried out during March and May 2004,
and targeted the general population of the CUA. All
inhabitants older than 2 years living in the study site were
eligible to participate in the survey. A cross-sectional study
design was used to achieve the primary objective: to esti-
mate the prevalence of HCV seropositivity and evaluate
potential risk factors by comparing HCV seropositive and
seronegative individuals. A two-stage cluster sampling
technique, according to the Expanded Programme on
Immunization (EPI) cluster survey approach, was
employed to obtain the required sample. A cluster was
defined as a "Fokontany", the smallest administrative
unit. The sampling unit was a household randomly
selected within each cluster.
Sample size
Using EPI Info software and assuming a HCV seropreva-
lence of 1.2% in the study population with 95% confi-
dence level, error limits of +/-1% and a design effect of 2,
the estimated sample size required was 2234. However,
the target sample size was increased to 2310, made up of
70 clusters each with 33 subjects.
Data collection and serology
Physicians from the Ministry of Health of Madagascar and
Pasteur Institute of Madagascar went to the selected
household and approached the head of the family. They
explained the purpose and objectives of the study and
asked for written informed consent (from participants or
parents for minors) before administering the question-
naire and collecting a blood sample. The team adminis-
tered a pre-tested questionnaire to the participant to
obtain information on socio-demography and potential
risk factors for HCV transmission. The questions in the
questionnaire gathered demographic characteristics
including age, sex, socio-economic status, matrimonial
status (this variable was classified as subjects "living as a
couple, married or not" and "single"), and also the fol-
lowing information: number of years in education,
number of therapeutic injections, history of surgical pro-
cedure, especially circumcision for men, transfusion with
blood or blood products, history or current use of intrave-
nous drugs, history of tattooing or scarification, history of
jaundice, history of HBV immunization and history of tra-
ditional medicine use.
Each blood sample was analyzed first with a third genera-
tion ELISA, Monolisa® anti-HCV Plus version 2, (BioRad,
Marne-La-Coquette, France) according to the recommen-
dations of the manufacturer. Positive sera were retested
using an immunoblot test, Deciscan®  HCV Plus assay
(Biorad, Marne-La-Coquette, France) to confirm theBMC Infectious Diseases 2008, 8:25 http://www.biomedcentral.com/1471-2334/8/25
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results. All Monolisa-positive samples and pools of 10
negative sera were screened for the presence of viral RNA
using reverse transcription polymerase chain reaction
amplifying the 5'untranslated region (UTR). The genotype
was determined using the BLAST tool with another 5'UTR
fragment as described previously [25]. If results with both
the Monolisa test and the Deciscan were positive, the sub-
ject was considered to be seropositive for HCV.
Data management and analysis plan
EPI Info version 6 was used for data entry [EPI Info: a word
processing database and statistics program for public health;
Version 6. Atlanta, GA: Center for Disease Control and Pre-
vention; 1995]. The data was analyzed using the Statistical
Package for Social Sciences (SPSS) version 11.5 [SPSS. Sta-
tistical Package for Social Sciences; Version 10.0. Chicago, IL:
SPSS Inc; 1996]. The analysis was carried out at three lev-
els: descriptive analysis, and univariate and multivariate
analyses. Descriptive statistics of socio-demographic vari-
ables and other characteristics of the sampled population
were computed. Means and standard deviations (SD)
were calculated for quantitative variables and proportions
for categorical variables. Logistic regression analysis was
performed to measure the association between outcome
and each independent variable. Odds ratios (OR) and
95% confidence intervals (CI) were calculated from β
coefficients and their standard errors. Associations
between independent variables were assessed using
appropriate tests before performing multivariate analysis.
A multivariate logistic regression model was employed
with stepwise backward elimination of non-significant
variables, with HCV antibody status as the dependent var-
iable. P values < 0.05 were considered to be statistically
significant.
Ethical clearance
The study was approved by the Ministry of Health and the
National Ethics Committee of Madagascar. Permission
and informed consent were obtained from the Antanan-
arivo district and the participants of the study.
Results
Among the 2,310 subjects contacted for the study, 2,169
older than two years (94%) agreed to participate and had
serum tested for HCV antibody. Most subjects who were
informed of the study agreed to participate, the exact
number of subjects who refused participation was not
determined. The mean age of the 2169 subjects was 29.1
years (CI95% [28.3–29.8]). The sex ratio was 0.62 (834
males/1335 females).
Of the 2,169 sera collected, 36 (1.6%) scored positive in
the Monolisa anti HCV test version 2. The 36 positive
samples were re-tested using Deciscan HCV Plus: 25 were
confirmed positive for anti-HCV (1.2% with 95% CI
[0.75–1.72], eight were indeterminate and three negative.
Of the 36 subjects positive for anti-hepatitis C antibody
(Monolisa), 17 (47.2%) were positive for HCV-RNA (16
positive and 1 indeterminate by Deciscan). Thus, the prev-
alence of active HCV infection in the study population
was 0.8% (17/2169). Nine of the positive samples
(52.9%) contained genotype 1 (subtype 1b) HCV, and
eight genotype 2 (47.1%).
The prevalence was not significantly different according to
gender (males: 1.1% (9/834), females: 1.2% (16/1335); p
= 0.8) but HCV seropositivity and HCV RNA positivity
increased with age (Table 1) (Chi2 tendency test, p < 10-
2). There were no other statistically significant differences
between the anti-HCV positive and anti-HCV negative
groups in terms of demographic characteristics or ritual
practices including circumcision and scarification (Table
2). Of note, male circumcision was a frequent ritual prac-
tice (96.4%). Thirteen of the 25 subjects with anti-HCV,
but only 692 of 2142 anti-HCV negative subjects, reported
a history of hospitalization (p = 0.04).
The percentage of individuals having received previous
dental treatment was significantly higher among anti-
HCV positive (88%) than among anti-HCV negative
(61.4%) subjects (p < 10-2). The percentage of individuals
with a history of blood transfusion was not significantly
different between the anti-HCV positive (16.0%) and
anti-HCV negative (5.9%) groups.
Table 1: Seroprevalence of anti-Hepatitis C and risk factors according to age group among Antananarivo inhabitants in 2004.
Age group (years) P value
0 – 24 yrs (n = 1018) 25 – 44 yrs (n = 688) 45 – 64 yrs (n = 372) > 64 yrs (n = 91)
Anti-HCV positive 1 (0.1) 7 (1.2) 10 (2.7) 7 (7.7) <10-2
HCV RNA positive 0 (0.0) 2 (0.3) 8 (2.2) 7 (7.7) <10-2
Previous therapeutic injections 756 (74.3) 607 (88.3) 348 (93.5) 86 (94.5) <10-2
Previous blood transfusion 11 (2.1) 52 (7.6) 58 (15.6) 10 (10.9) <10-2
Previous dental treatment 442 (43.5) 528 (76.8) 300 (81.1) 66 (72.5) <10-2
ALT abnormal 20 (1.9) 17 (2.5) 11 (2.9) 2 (2.2) <10-2
AST abnormal 152 (14.9) 63 (9.1) 53 (14.2) 11 (12.1) <10-2BMC Infectious Diseases 2008, 8:25 http://www.biomedcentral.com/1471-2334/8/25
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All HCV-positive subjects had received therapeutic injec-
tions whereas none of those who did not receive an injec-
tion was anti-HCV positive. The proportion of anti-HCV
positives increased with the number of therapeutic injec-
tions (Chi2 tendency test, p < 10-2): 0.7% (8/1053)
between 1 to 10 injections, 0.9% (2/221) between 11 to
15 injections and 2.7% (14/521) for more than 15 injec-
tions.
Few subjects (4/2067) reported intravenous drug use: 1/
22 subjects with HCV antibodies and 3/2049 anti-HCV
negative subjects (p = 0.04); intravenous drug use was sig-
nificantly associated with anti-HCV positivity (Table 2).
Finally, as expected, high aminotransferase (ALT and AST)
activity was significantly associated with anti-HCV posi-
tivity, and hepatic enzyme (ALT, AST) activities were high
in the 17 subjects with active HCV infection.
The major channels for HCV transmission (blood transfu-
sion, therapeutic injections, dental treatment) are all
related to age and increased with age up to the [45–64 yrs]
age group (Table 1).
In the multiple logistic regression model with backwards
elimination, only age and aminotransferase (AST) were
independently associated with a positive HCV antibody
result (Table 3).
Discussion
This survey indicates that the seroprevalence of HCV anti-
bodies in Antananarivo is low (1.2%) and similar to val-
ues reported by previous studies in Madagascar. In 1994,
Zeller et al. found a prevalence of 1.2% in the general pop-
ulation of Antananarivo and Toamasina provinces [23].
This prevalence is similar to rates reported for the south
and east of Africa (1.6% for the general population, 1.9%
for blood donors) [14]. In this region, Mozambique
(2.8%) and Tanzania (3.2%) have the highest HCV prev-
alence. The prevalence in Madagascar is lower than the
sub-Saharan African median of 2.2% [14].
We have no information about the subjects who refused
to participate in the study, and this may limit the repre-
sentativeness of the sample. Other limitations of the study
are linked to the difficulties inherent in self-reporting of
behaviour, including in particular drug use, to the lack of
Table 2: Demographic features and risk factors associated with seroprevalence of anti-Hepatitis C (Univariate analysis) among 
Antananarivo inhabitants in 2004.
Anti-hepatitis C antibody
Risk factor Positive n (%) Negative n (%) P value
Matrimonial status In couple 18 (75.0) 977 (61.6)
Single 6 (25.0) 609 (38.4) 0.17
Educational level Educated 17 (68.0) 1259 (58.7)
Non-educated or low level 8 (32.0) 885 (41.3) 0.35
Circumcision No 0 (0.0) 30 (3.6)
Yes 9 (100.0) 795 (96.4) 0.99
Previous scarification No 24 (96.0) 2109 (99.2)
Yes 1 (4.0) 17 (32.3) 0.19
Previous hospitalisations No 12 (48.0) 1452 (67.7)
Yes 13 (52.0) 692 (32.3) 0.04
Previous jaundice No 23 (92.0) 1968 (92.7)
Yes 2 (8.0) 155 (7.3) 0.70
Previous therapeutic injections No 0 (0.0) 371 (17.3)
Yes 25 (100.0) 1772 (82.7) 0.01
Previous surgical operation No 17 (70.8) 1808 (84.6)
Yes 7 (29.1) 330 (15.4) 0.08
Blood transfusion No 21 (84.0) 2017 (94.1)
Yes 4 (16.0) 127 (5.9) 0.06
Dental treatment No 3 (12.0) 825 (38.6)
Yes 22 (88.0) 1314 (61.4) <10-2
Intravenous drug use No 21 (95.5) 2046 (99.8)
Yes 1 (4.5) 3 (0.2) 0.04
Tattooing No 20 (86.9) 1874 (89.4)
Yes 3 (13.1) 222 (10.6) 0.45
Aminotransferase (ALT) Normal 22 (88.0) 2055 (97.7)
Abnormal 3 (12.0) 47 (2.3) 0.02
Aminotransferase(AST) Normal 16 (64.0) 1832 (87.1)
Abnormal 9 (36.0) 270 (12.9) <10-2BMC Infectious Diseases 2008, 8:25 http://www.biomedcentral.com/1471-2334/8/25
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clinical information (acute or chronic liver disease, dialy-
sis) and of individual information for some of the risk fac-
tors.
In the developing world, which includes Madagascar, the
prevalence of HCV is thought to be both higher and dis-
tributed more generally throughout the adult population
than in industrialised countries [1]. Given the low trans-
mission of HCV through sexual contact in sub-Saharan
Africa [14] and rarity of intravenous drug use in Madagas-
car, the observed increase of anti-HCV seroprevalence
with age is suggestive of unsafe medical practices
(unsterile injections and other iatrogenic routes of trans-
mission) as the main risk factor for HCV infection. In the
Commune Urbaine d'Antananarivo (CUA), all cases had a
history of previously receiving therapeutic injections and
the analysis of risk factors according to age group possibly
suggests a cumulative effect: the risk increases with the
number of therapeutic injections.
Enzyme immunoassays and PCR assay indicated increas-
ing prevalence with age, suggesting that there may be
ongoing and repeated exposures to HCV infection, possi-
bly through the medical care system. However, a large
proportion of anti-HCV seronegative individuals had also
had injections. Moreover, not only HCV prevalence
increased with age, but also the blood exposure risk.
(Moreover, both HIV and blood exposure risk increased with
age.)
Univariate analysis showed that dental treatment and pre-
vious injections increased the risk HCV seropositivity.
This could be explained by the lack of prevention in
healthcare (poor sterilization procedures, unsafe injec-
tions) in Madagascar. Until the early 1990s, most primary
health care programs were supplied with glass or plastic
syringes designed to be washed and sterilized between
uses. Earlier, boiling was deemed acceptable for decon-
taminating these syringes, but evidence on the thermosta-
bility of resistant spores and hepatitis viruses prompted a
change to steam sterilizers or pressure cookers. These
decontamination procedures were highly dependent
upon the availability of fuel for heating, regular mainte-
nance of the sterilizers, availability of spare parts, well-
trained health care workers, and good management and
control procedures. Lack of one or more of these essential
conditions often resulted in the use of contaminated
injection equipment. The introduction of disposable
syringes and needles designed for single use tended to
exacerbate the problem because the conditions and cul-
ture of scarcity still prevailed; disposable products could
be easily reused, and they were not designed to be cleaned
and sterilized.
Half of the more than 16 billion injections administered
in the developing world have been estimated to be unsafe
[26]. More recently, health officials estimate that annu-
ally, the re-use of injection equipment may cause 20 mil-
lion infections with hepatitis B virus, 2 million infections
with hepatitis C virus and 250,000 infections with HIV
worldwide [27].
It should be stressed that in our study, the prevalence of
HCV infection was not associated with blood transfusion.
This observation is surprising in view of the recent intro-
duction (around 2000, report from MOH) of anti-HCV
screening tests in hospital blood centres in the CUA. Pre-
sumably, the reservoir levels of the virus in blood in the
CUA are low. But this observation concerning blood
transfusion contrasts with many studies elsewhere in the
world6, and also with a previous survey (in 1994) of the
general population in two provinces of Madagascar where
a significant relationship was found between history of
blood transfusion and HCV infection [23]. The most obvi-
ous difference between our results and this prior study
was that the previous study included both urban and rural
subjects, whereas we collected data only in an urban set-
ting. It is reasonable to assume that information bias
could affect the result. HCV is transmitted mainly through
contact with blood and blood products, and this includes
blood transfusions. However, with the advent of routine
blood screening for HCV antibodies (in 1991 in most
Table 3: Independent risk factors associated with seroprevalence of anti-Hepatitis C among Antananarivo inhabitants identified by 
multiple logistic regression, Antananarivo, 2004.
Risk factor Adjusted odds ratio 95% confidence interval (CI) P value
Age
0 – 24 1.0 (1.3 – 85.3) 0.02
25 – 44 10.4 (3.6 – 220.5) <10-2
44 – 64 28.1 (10.3 – 697.7) <10-2
65 & more 84.7
Aminotransferase (AST)
Normal 1.0
Abnormal 4.4 (1.8 – 10.3) <10-2BMC Infectious Diseases 2008, 8:25 http://www.biomedcentral.com/1471-2334/8/25
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countries), transfusion-related hepatitis C has almost dis-
appeared. In developing countries, routine blood screen-
ing is better available in urban than rural settings.
As in other studies [28-30], we identified illegal intrave-
nous drug use as a mode of HCV transmission. Neverthe-
less, the small number of subjects who admitted
intravenous drug use makes definitive conclusions diffi-
cult. Intravenous drug use could not explain the preva-
lence of HCV antibodies in the study population.
The absence of positive young children is consistent with
mother-to-child transmission being rare in Madagascar as
described previously [23] and more generally in the epide-
miology of HCV [14].
Detection of serum anti-HCV antibodies is indicative of
past or active infection. HCV viraemia, as assessed by RT-
PCR, is a much more accurate indicator of chronic hepati-
tis due to virus [31]. We found a prevalence of active HCV
infection of 0.8% in the study population, lower than the
5.7% reported for Morocco population [32] and the 2.3%
reported in Sudan [33]. More than half the isolates
(52.9%) were subtype 1b. Genotype 1b is also the most
prevalent in many other countries [34]. Note that geno-
type 1b is less responsive than genotypes 2 and 3 to alpha-
interferon therapy [34]. However, incomes in Madagascar
are so low that few patients can afford treatment.
Conclusion
In conclusion, these results for an urban population in
Antananarivo indicate that the prevalence of HCV has not
increased since a previous study in Madagascar [23]. Our
findings suggest that the rate of HCV infection in Mada-
gascar has been low and raise questions about the reser-
voir levels and iatrogenic transmission. This study
contributes to our understanding of the worldwide preva-
lence of hepatitis C, which in turn facilitates informed
decisions regarding the priorities of funding for the treat-
ment, prevention and surveillance of this infection.
Research in this field will need to be continued and in par-
ticular targeting rural populations. The incidence of the
virus elsewhere in Madagascar should be evaluated, and
the transmissibility of the various genotypes should be
assessed. Better prevention, screening and treatment
methods for Hepatitis C virus all need to be identified and
described. However, in view of our findings, there is a
need to educate general population regarding HCV infec-
tion and the risks associated with inappropriate therapeu-
tic injections.
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